Search Results

You searched for : anti-PD-1  

Zumutor Biologics Advances Cancer Care with Novel Immunotherapy ZM008: A First-in-Class Anti LLT1 Antibody

As the ZM008-001 clinical trial progresses, the medical community eagerly awaits the results, which could lead the way for a new era in cancer ...
Jun 13

Evaxion Biotech announces Clinical Collaboration to evaluate Keytruda in melanoma patients

Latest news updates...
Oct 26

ImmixBio and BeiGene to evaluate combination of IMX-110 and Tislelizumab in solid tumors

Latest Pharma News Update...
Aug 31

Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106

Latest Pharma Update...
Aug 23

GSK and iTeos Therapeutics announce development and commercialisation collaboration for EOS-448

With this collaboration GSK is uniquely positioned with access to antibodies that synergistically target all three known CD226 checkpoints - TIGIT, CD96 and PVRIG....
Jun 14

Bristol Myers Squibb announces LAG-3-Blocking antibody Relatlimab and Nivolumab fixed-dose Combination

Significantly improves progression-free Survival vs. Opdivo (nivolumab) in patients...
May 22

Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo

The antibody is indicated for patients with previously untreated Metastatic or unresectable melanoma...
Mar 27

BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid tumors

BioInvent and Transgene, today announced they have received regulatory approval in Belgium for a clinical trial application (CTA) for a Phase l/lla study of ...
Dec 21

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA

...
Dec 18

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA

Patients with newly diagnosed esophageal and GEJ cancer face an aggressive disease with a poor prognosis, despite the currently available treatment options...
Dec 17

KEYTRUDA Plus LENVIMA Combination Demonstrated Statistically Significant Improvement in Overall Survival

...
Dec 16

Merck Receives Positive EU CHMP Opinion for KEYTRUDA as First-Line Treatment for Metastatic Microsatellite Instability

...
Dec 11

KEYTRUDA plus LENVIMA met the trial’s primary endpoint of progression-free survival

LENVIMA plus everolimus were evaluated versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma...
Nov 10

Dr. Reddy’s E777 ( Denileukin Diftitox) pre clinical data shows tumor growth inhibition

...
Nov 10

Merck received US FDA approval for Keytruda

FDA approves expanded indication for Merck’s KEYTRUDA (pembrolizumab) in adult patients with relapsed or refractory classical hodgkin lymphoma (cHL) ...
Oct 16

FDA Approves Expanded Indication for Merck’s KEYTRUDA in Adult Patients With classical Hodgkin Lymphoma (cHL)

...
Oct 15

Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1

Positive pivotal trial data for the investigational use of PD-1 inhibitor Libtayo® (cemiplimab) in first-line locally advanced or metastatic non-small cell lung ...
Sep 21

Junshi Biosciences receives FDA Breakthrough Therapy Designation for Toripalimab

Major breakthrough for treatment of Nasopharyngeal Carcinomar ...
Sep 11

Merck’s KEYTRUDA Receives Two New Approvals in Japan

Keytruda would be soon launched in Japan for the treatment of cancerous tumors...
Aug 27

Compugen Reports 4th Quarter and Full Year 2019 Result

Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today declared their 4th and full year report....
Feb 21

20 Matching result(s) found!

-Advertisements-




Trending Now

Scientists in Moscow Develop Fetal Phantom for Obstetric UltrasoundNovember 19, 2024
International Men’s Day: A Celebration of Strength, Vulnerability, and ChangeNovember 19, 2024
The Bloody Truth: Why Menstruation Is Still a Taboo in Indian SchoolsNovember 19, 2024
Toxic Air, Fragile Hearts: The Hidden Cost of Pollution on Heart Failure PatientsNovember 19, 2024
Government of Telangana Hosts the AI in Healthcare Summit – Road to BioAsia 2025November 18, 2024
In yet another groundbreaking medical milestone, Sarvodaya Hospital successfully performs India’s youngest cochlear implant on a 5- month old babyNovember 18, 2024
Sightsavers India in collaboration with AbbVie Therapeutics India Private Limited Hosted the 4th State-Level Consultation on ‘Prevention of Visual Impairment Caused by Glaucoma’November 16, 2024
Is Your Saree Hurting You? How Tight Waist Petticoats Could Trigger Skin CancerNovember 16, 2024
10 New-born Lives Lost: The Jhansi Hospital Fire That Shook India’s ConscienceNovember 16, 2024
Streax introduces revolutionary Shampoo Hair Colour in South India at accessible price point.November 15, 2024
The Silent Killer in Your Genes: Can Splicing Errors Unlock New Cancer Cures?November 15, 2024
Stress on a Schedule: What Your Gut Bacteria Know That You Don’tNovember 15, 2024
A Preventable Catastrophe: Why Are Children Still Dying from Measles?November 15, 2024
The University of Tasmania invites applications for Master of Marine and Antarctic ScienceNovember 14, 2024
ICMR’s Bold Bet: Can India’s Scientists Deliver World-First Health Breakthroughs?November 14, 2024
The Dark Reality Behind India’s Ayushman Bharat: Profits Before Patients?November 14, 2024
Not a Fan of Exercise? Here’s How Few Steps You Actually Need for Better HealthNovember 14, 2024
Shiprocket launches AI Powered Shiprocket Copilot to empower a Self-Reliant Digital Future for over 1,00,000+ Indian MSMEsNovember 13, 2024
AIIMS Darbhanga and More: Can PM Modi’s 12,000 Crore Investment Turn Bihar into India’s Next Growth Engine?November 13, 2024
Self-Made Survivor: How a Virologist Battled Breast Cancer with Her Own Lab-Grown VirusesNovember 13, 2024